HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Coppola, V. Articles by Bonci, D. PubMed PubMed Citation Articles by Coppola, V. Articles by Bonci, D.

V Coppola, Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
R de Maria, Laboratorio di Ematologia e Oncologia, Istituto Superiore di Sanità, I-00161, Italy
D Bonci, Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

Ruggero de Maria, Email: demaria{at}iss.it

Abstract

Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour-suppressor genes, thus envisaging their use as diagnostic, prognostic and therapeutic biomolecules. This review extensively and critically summarizes the current knowledge about microRNA deregulation in prostate cancer disease, underlining present limits and future perspectives.